Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai’s Sleep Inducer Dayvigo Now Available in Hong Kong
July 1, 2021
- AbbVie Japan Files Rinvoq for Ankylosing Spondylitis
July 1, 2021
- Taisho Grants Worldwide Rights for Antidepressant TS-121 to US Firm
July 1, 2021
- New BMS Japan Boots Up with Richer Cancer Assets as Celgene Merger Closes
July 1, 2021
- 2 Ono Employees Found Guilty for Onoact Bribery Charges; Scholarship Donation in Spotlight
June 30, 2021
- Chugai Files Regeneron’s Antibody Cocktail in Japan
June 30, 2021
- Japan Top Court Rejects Prosecutors’ Appeal in Diovan Case; Novartis Not Guilty
June 30, 2021
- Takeda CEO Takes Home 1.87 Billion Yen in FY2020
June 30, 2021
- Takeda’s Leuplin Supply Curb Remains More than 1 Year after Measure Set Off
June 29, 2021
- Organon Japan to Focus on Women’s Health, Enrich Offerings with Global Products: President
June 29, 2021
- HIF-PH Med Roxadustat Gets EU Panel Backing: Astellas/FibroGen
June 29, 2021
- Kaken Files Japan NDA for Eschar Remover KMW-1
June 29, 2021
- Kissei Licenses Out South Korean Rights for Fostamatinib
June 29, 2021
- Novo’s Smart Insulin Pens Get Japan Approval, Launch in H1 2022
June 28, 2021
- Otsuka Seeks EU Nod for Lupus Nephritis Drug
June 28, 2021
- CellCept Gets Additional Nod for GVHD in HSCT: Chugai
June 28, 2021
- Sumitomo Dainippon Chief’s Pay Tops 100 Million Yen
June 28, 2021
- MSD Chief Wants Japan to Eliminate Disincentives Tied to Re-Pricing Rules as Keytruda Faces Repeated Cuts
June 28, 2021
- Sawai Expands Shipment Adjustments to 369 Products
June 28, 2021
- Biosimilar Momentum Unabated in Japan Even with Supply Concerns
June 25, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…